IndiviorINDV
INDV
About: Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
Employees: 1,164
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
554% more call options, than puts
Call options by funds: $962K | Put options by funds: $147K
19% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 21
11.28% more ownership
Funds ownership: 61.94% [Q4 2024] → 73.22% (+11.28%) [Q1 2025]
3% more funds holding
Funds holding: 111 [Q4 2024] → 114 (+3) [Q1 2025]
11% less capital invested
Capital invested by funds: $974M [Q4 2024] → $866M (-$108M) [Q1 2025]
18% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 40
50% less funds holding in top 10
Funds holding in top 10: 8 [Q4 2024] → 4 (-4) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for INDV.
Financial journalist opinion
Based on 4 articles about INDV published over the past 30 days
Negative
Proactive Investors
1 week ago
Indivior brings curtain down on turbulent 11-year run in London
Indivior PLC (LSE:INDV) is set to end its secondary listing on the London Stock Exchange, drawing a line under a volatile 11-year chapter as a UK-listed company following its spin-out from Reckitt Benckiser in 2014. Its tenure as a London-listed company was marred by legal battles over its opioid treatments, loss of patent protection, investor distrust, and a growing disconnect between its UK listing and US-focused operations.
Neutral
Reuters
1 week ago
Indivior to delist from London Stock Exchange, maintain Nasdaq listing
Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align with its U.S.-centric business.
Neutral
PRNewsWire
1 week ago
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
SLOUGH, England and RICHMOND, Va. , June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "London Delisting").
Neutral
PRNewsWire
2 weeks ago
Indivior Announces Patrick Barry as Chief Commercial Officer
Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va. , May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2.
Neutral
PRNewsWire
1 month ago
Indivior to Participate in Upcoming Investor Events
RICHMOND, Va. , May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New York City, NY Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 4 th.
Neutral
PRNewsWire
1 month ago
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy
SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder During Pregnancy" in the American Journal on Addictions, evaluating the use of SUBLOCADE for the treatment of opioid use disorder (OUD) during pregnancy and postpartum.
Neutral
Seeking Alpha
1 month ago
Indivior: Trying To Break Addiction
Indivior PLC's stock has seen headwinds recently due to increasing competition and poor performance but has potential for recovery with a new CEO and strategic changes. Sublocade, Indivior's key product franchise, faces competition but shows promise with expanded FDA approval and a stabilizing market share. Despite litigation risks and financial challenges, analysts remain optimistic, projecting growth in the buprenorphine market and potential stock recovery.
Neutral
Seeking Alpha
1 month ago
Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript
Indivior PLC (NASDAQ:INDV ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Jason Thompson - Head, IR Mark Crossley - CEO Ryan Preblick - CFO Conference Call Participants Carl Burns - Northland Capital Markets David Amsellem - Piper Sandler Christian Glennie - Stifel Chase Knickerbocker - Craig-Hallum Thibault Boutherin - Morgan Stanley Paul Cuddon - Deutsche Numis Operator Good day and thank you for standing by. Welcome to the Indivior PLC Q1 2025 Financial Results Conference Call.
Positive
Zacks Investment Research
1 month ago
Indivior PLC (INDV) Q1 Earnings and Revenues Beat Estimates
Indivior PLC (INDV) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.37 per share a year ago.
Neutral
PRNewsWire
1 month ago
Indivior Announces Q1 2025 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025.
Charts implemented using Lightweight Charts™